uniQure applies for U.S. approval after FDA reverses stance
uniQure said it has applied for U.S. approval of its experimental Huntington’s disease gene therapy after the FDA reversed its earlier position; shares were up 5% in premarket trading.
Dutch gene therapy developer uniQure NASDAQ:QURE said on Wednesday it had applied for U.S. approval of its experimental treatment for Huntington's disease after the FDA reversed its earlier position on the drug, sending the company's shares up 5% in premarket trading.Huntington's disease is a rare…